Ani Pharmaceuticals INC Form 4 insider transactions

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock at $57.19 per share on October 14, 2024, according to a Form 4 filing.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock at $56.82 per share on September 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, reports the disposition of 1,486 shares of common stock to cover tax obligations related to vesting restricted stock.

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, reports the disposition of 3,646 shares of common stock to cover tax obligations related to vesting restricted stock.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock at $59.62 per share on August 13, 2024, under a pre-arranged 10b5-1 trading plan.

Muthusamy Shanmugam, Head of R&D and COO-Novitium Operations at ANI Pharmaceuticals, sold 2,743 shares of common stock at a weighted average price of $62, according to a Form 4 filing.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, reports disposition of shares for tax purposes related to vesting of restricted stock.

Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold shares of common stock between July 15 and July 17, 2024, under a pre-arranged trading plan.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock on July 12, 2024, at a price of $64.91 per share.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock at a weighted average price of $63.44 on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Muthusamy Shanmugam, a Director and Officer at ANI Pharmaceuticals, sold 20,000 shares of common stock at an average price of $58.90, according to a recent SEC filing.

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, sold shares of common stock between June 17 and June 20, 2024, under a pre-arranged trading plan.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock on June 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James G. Marken, SVP of Operations & Product Development at ANI Pharmaceuticals, exercised stock options and sold shares on June 7, 2024, while also correcting a previous reporting error.

Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, sold 2,985 shares of common stock on June 5, 2024, at a price of $67 per share.

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, sold 5,000 shares of common stock on June 4, 2024, at a weighted average price of $63.58.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock at a weighted average price of $64.41 on June 3, 2024, according to a Form 4 filing.

Patrick D. Walsh, a director at ANI Pharmaceuticals, acquired 4,410 shares of common stock through a restricted stock award that vests on May 21, 2025.

Director Jeanne Thoma acquired 4,410 shares of ANI Pharmaceuticals common stock through a restricted stock award that vests on May 21, 2025.

Director Renee P. Tannenbaum acquired 4,410 shares of ANI Pharmaceuticals common stock through a restricted stock award that vests on May 21, 2025.

Director Antonio R. Pera acquired 4,410 shares of ANI Pharmaceuticals common stock through a restricted stock award that will vest on May 21, 2025.

Matthew J. Leonard, a director of ANI Pharmaceuticals, acquired 4,410 shares of common stock and granted a power of attorney for SEC filings.

Director Thomas Haughey of ANI Pharmaceuticals acquired 4,410 shares of common stock through a restricted stock award that vests on May 21, 2025.

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, sold 2,000 shares of common stock at a price of $61.61 on May 21, 2024.

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, sold 12,855 shares of common stock on May 20, 2024, under a pre-arranged trading plan.

Director and Officer of ANI Pharmaceuticals, Muthusamy Shanmugam, executed multiple sales of common stock between May 15 and May 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Renee P. Tannenbaum sold 2,000 shares of ANI Pharmaceuticals Inc. on May 16, 2024, at a price of $63.87 per share.

ANI Pharmaceuticals' President and CEO, Nikhil Lalwani, sold 16,669 shares of common stock on May 14, 2024.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of ANI Pharmaceuticals, sold 250 shares of common stock on May 13, 2024, at a price of $67.69 per share.

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.